INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments [Yahoo! Finance]
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. (PRNewsfoto/INOVIO Pharmaceuticals, Inc.) "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for patients suffering from a devastating rare disease and delivering on the promise of DNA medicines," said Dr. Jacqueline Shea , INOVIO's President and Chief Executive Officer. "Our top priorities for the coming year are the submission of our biologics license application (BLA) for INO-3107 and preparing to expedite the launch of the product commercially, should it be approved. We also look forward to making progress with our pipeline through collaborations and other potential
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)PR Newswire
- INOVIO Reports Inducement Grant Under Inducement PlanPR Newswire
- Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- INOVIO to Participate in December Investor ConferencesPR Newswire
INO
Earnings
- 11/10/25 - Miss
INO
Sec Filings
- 12/29/25 - Form 8-K
- 12/8/25 - Form SCHEDULE
- 12/5/25 - Form SCHEDULE
- INO's page on the SEC website